ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®

Completed

Conditions: Glabellar Lines

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2012-05-31

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 207

Registration Number: NCT01608672

An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A

Completed

Conditions: Facial Rhytides

Interventions: Drug: botulinum toxin Type A

First Posted Date: 2012-05-31

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 110

Registration Number: NCT01608659

A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery

Phase 1

Terminated

Conditions: Cataract

Interventions: Drug: Dexamethasone Drug Delivery System
Drug: Placebo Drug Delivery System

First Posted Date: 2012-05-25

Last Posted Date: 2015-07-01

Lead Sponsor: Allergan

Target Recruit Count: 8

Registration Number: NCT01605942

BOTOX® Treatment in Pediatric Lower Limb Spasticity

Phase 3

Completed

Conditions: Muscle Spasticity
Cerebral Palsy
Pediatrics

Interventions: Biological: botulinum toxin Type A
Drug: Normal Saline (Placebo)

First Posted Date: 2012-05-22

Last Posted Date: 2018-08-14

Lead Sponsor: Allergan

Target Recruit Count: 384

Registration Number: NCT01603628

Locations: 🇺🇸
Harrison Clinical Management, Pomona, California, United States
🇺🇸
AMS Neurology, Pasadena, California, United States
🇺🇸
Children's Healthcare of Atlanta Children's Rehabilitation Associates, Atlanta, Georgia, United States

and more 50 locations

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

Phase 3

Completed

Conditions: Pediatrics
Cerebral Palsy
Stroke
Muscle Spasticity

Interventions: Biological: Botulinum Toxin Type A

First Posted Date: 2012-05-22

Last Posted Date: 2019-08-21

Lead Sponsor: Allergan

Target Recruit Count: 220

Registration Number: NCT01603615

Locations: 🇺🇸
ABS Health, LLC, Pasadena, California, United States
🇺🇸
Harrison Clinical Management, Pomona, California, United States
🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States

and more 45 locations

BOTOX® Treatment in Pediatric Upper Limb Spasticity

Phase 3

Completed

Conditions: Muscle Spasticity
Pediatrics
Cerebral Palsy
Stroke

Interventions: Biological: botulinum toxin Type A
Drug: Normal Saline (Placebo)

First Posted Date: 2012-05-22

Last Posted Date: 2018-08-14

Lead Sponsor: Allergan

Target Recruit Count: 235

Registration Number: NCT01603602

Locations: 🇺🇸
Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States
🇵🇱
NZOZ Mazowieckie Centrum, Warsaw, Poland
🇹🇭
Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand

and more 42 locations

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

Phase 3

Completed

Conditions: Muscle Spasticity
Cerebral Palsy
Pediatrics

Interventions: Biological: Botulinum Toxin Type A

First Posted Date: 2012-05-22

Last Posted Date: 2019-08-21

Lead Sponsor: Allergan

Target Recruit Count: 370

Registration Number: NCT01603641

Locations: 🇺🇸
The Children's Mercy Hospital, Kansas City, Missouri, United States
🇵🇭
St. Luke's Medical Center, Quezon City, Philippines
🇵🇱
Uniwersytecki Dzieciecy Szpita, Białystok, Poland

and more 53 locations

Reliability of the Facial Wrinkle Scale in Japanese Subjects

Completed

Conditions: Facial Rhytides

Interventions: Drug: No Intervention

First Posted Date: 2012-05-17

Last Posted Date: 2013-09-30

Lead Sponsor: Allergan

Target Recruit Count: 66

Registration Number: NCT01600729

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Phase 3

Completed

Conditions: Multiple Sclerosis
Neurogenic Bladder
Urinary Incontinence

Interventions: Biological: OnabotulinumtoxinA
Drug: Placebo (Normal Saline)

First Posted Date: 2012-05-17

Last Posted Date: 2019-04-30

Lead Sponsor: Allergan

Target Recruit Count: 144

Registration Number: NCT01600716

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Phase 4

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Bimatoprost 0.01%

First Posted Date: 2012-05-09

Last Posted Date: 2014-01-28

Lead Sponsor: Allergan

Target Recruit Count: 800

Registration Number: NCT01594970

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy